About the Company
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ILMN News
Exclusive: Icahn drops Illumina board challenge threat, sources say
Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illumina's board, sparing the U.S. gene ...
Gene Sequencing Firm Illumina Escapes Carl Icahn's Second Proxy Battle Amid Grail Divestment Efforts
Carl Icahn halts new challenge to Illumina's board, sparing the gene sequencing giant a second proxy battle. Focus shifts to ...
Carl Icahn has called off the dogs hounding DNA-sequencing company Illumina
Victor J. Blue/Bloomberg—Getty Images Carl Icahn has decided not to launch a fresh proxy fight at DNA sequencing company ...
A Biobank for the Americas and a Genomics Lab Power Precision Health for All
When it came to collecting genetic samples, Bustamante prioritized diversity. As a Venezuelan American, he recognized the importance of representing Hispanic Latinos adequately in genetic datasets.
Illumina Board Sued by Pension Fund During Fight With Icahn
A pension fund is suing Illumina Inc.'s senior leaders over its failed $7 billion acquisition of Grail Inc., a transaction ...
Carl Icahn Drops Plans for New Proxy Fight at Illumina
Carl Icahn has decided not to launch a fresh proxy fight at DNA sequencing company Illumina Inc. this year, a person familiar ...
Illumina, Inc.: New Management Team Is Trying to Turn Illumina's Story Around
Find the latest Illumina, Inc. (ILMN) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...
Activist Icahn drops threat to start another proxy battle with Illumina - Reuters
Activist investor Carl Icahn has dropped a threat to start a new proxy battle with gene sequencing company Illumina, according to a Reuters report on Tuesday, which cited people familiar with the ...
Europe's Highest Court Affirms 'Broad' Opportunities for Intervention by Professional Associations
4 Order of the General Court, 19 July 2023, Illumina Inc. v European Commission, T‑709/22, ECLI:EU:T:2023:416. 5 Para. 49. 6 See Court of Justice, Order of the Vice-President, 22 February 2022, ...
Biotech group backs anti-China bill; part ways with WuXi AppTec
Biotech trade group BIO backs the proposed anti-china bill, the BIOSECURE Act, and part ways with its main target WuXi AppTec ...
Illumina: A Biobank for the Americas and a Genomics Lab Power Precision Health for All
NORTHAMPTON, MA / ACCESSWIRE / March 18, 2024 / Illumina: At Galatea Bio, Carlos D. Bustamante enriches the diversity of genomic datasets and brings precision medicine to underserved populations ...
Carl Icahn Said to Drop Plans for New Illumina Proxy Fight
Carl Icahn has decided not to launch a fresh proxy fight at DNA sequencing company Illumina Inc. this year, a person familiar with the matter said.
Loading the latest forecasts...